| Welcome |
| Welcome to the first India & US Fine and Pharmaceutical Chemicals e-newsletter, which will be sent to you each month. As India & US Fine and Pharmaceutical Chemicals e-newsletter editor, I hope this newsletter will provide an insightful and informative look at these intertwined, dynamic industries that are constantly on the go in a changing global healthcare environment. |
| The content will include hand-picked stories and selected feature articles from ICB, our 24-hour online ICIS News service, and relevant industry sources. The goal is to provide a pertinent snapshot of the pharmaceuticals and fine chemicals industries, track the moves of key players, and trace the pulse of these industries. |
| This month’s newsletter deals with recent developments in the EU, which has begun to acknowledge the danger that counterfeit drugs pose to its domestic markets. EU authorities are now calling for harsher legislation to prevent the easy flow of these counterfeits on to European shores. |
| Further in, we see Indian fine chemicals firm Dishman expanding its global products basket with the acquisition of Netherlands-based Solvay Pharmaceuticals’ fine chemicals and vitamin D businesses. Meanwhile, drug giant Merck has suffered some drawback in its second quarter earnings due to expenditures related to its acquisition of Swiss biotechnology firm Serono. |
| Tying in with the theme of India as a growing global player, we also present a recently featured ICB article on the radically shifting landscape of India from a mainly generics-driven industry to an innovative, drug-discovery engine. |
| I welcome your feedback on content and delivery at any time. |
Feliza Mirasol
India & US Fine and Pharmaceutical Chemicals e-newsletter editor
Tel: +212-791-4223
E-mail: feliza.mirasol@icis.com
Website: www.icis.com
|
| ˆ Top |
| EU must curb counterfeit drugs |
| The EU must develop a better system to stop the flow of counterfeit drugs into the region, where roughly 80% of generics are imported with very little or no control. The recognition of a counterfeit problem in Europe by large Western pharmaceutical companies is a positive move. |
| ˆ Top |
| Dishman purchases Solvay units |
| India’s Dishman Pharmaceuticals & Chemical Limited has acquired Solvay Pharmaceuticals’ fine chemicals, vitamin D and vitamin D analogues businesses for an undisclosed amount. The intended sale is a result of Netherlands-based Solvay’s strategy to focus on the main therapeutic areas of cardiometabolic and neuroscience treatments. |
| ˆ Top |
| Merck’s Q2 operating results climb 57.6% |
| Merck second quarter operating results were up 57.6% year on year to $386m (€278m) but earnings before interest and tax were down 84% due to expenditure related to the acquisition of Serono. R&D costs are on the rise as the company focuses on innovative, high value products. |
| ˆ Top |
| India drug discovery thrives in competitive R&D market |
| The global pharmaceutical industry is rallying to infuse flagging pipelines with innovative new drugs. But outsourced drug discovery is expected to gain, and India, intensifying its activities in chemistry, biology, and research capabilities, will be a winner. |
| ˆ Top |
 |
